Key Takeaways CLOV posted a Q4 adjusted loss of 5 cents per share, in line with estimates, while revenues rose 44.7% y/y.Insurance revenues rose 46.9% on 38% Medicare Advantage membership growth and strong retention.CLOV raised the 2026 revenue view to $2.81-$2.92B and sees GAAP net income of $0-$20M.Clover Health Investments, Corp. (CLOV) delivered an adjusted fourth-quarter 2025 loss per share of 5 cents, against the year-ago period’s adjusted earnings per share (EPS) of 2 cents. The bottom line was in li ...

Clover Health Investments (NasdaqGS:CLOV) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsAndrew Toy - CEOJohn Pinney - Senior Equity Research AssociatePeter Kuipers - CFONone - Company RepresentativeConference Call ParticipantsJonathan Yong - Executive Director, Equity Research AnalystOperatorHello, and welcome to Clover Health's fourth quarter 2025 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given in ...

Alignment Healthcare (NasdaqGS:ALHC) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsJim Head - CFOJohn Kao - Founder and CEOJohn Ransom - Managing Director in Equity ResearchJohn Stansel - Equity Research VPSam Becker - Goldman SachsTiffany Yuan - BarclaysConference Call ParticipantsCraig Jones - Healthcare AnalystJessica Tassan - Vice President and Senior Research Analyst in Healthcare IT and Delivery SectorJonathan Yong - Executive Director and Senior Equity Research AnalystMatthe ...

Clover Health Investments (NasdaqGS:CLOV) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Speaker3Hello, and welcome to Clover Health's fourth quarter 2025 earnings call. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. Ryan, you may begin.Speaker5Good afternoon, everyone. ...

Group 1 - CVS Health Corp. reported sales of $105.69 billion, exceeding the consensus estimate of $103.59 billion [1] - Adjusted earnings were $1.09 per share, surpassing the analyst estimate of 99 cents, but decreased from $1.19 in the prior year [1] - The company reaffirmed its fiscal 2026 adjusted earnings guidance of $7.00-$7.20 per share, compared to the Street consensus of $7.17, indicating a strong position for 2026 [1] Group 2 - CVS updated its cash flow from operations guidance to at least $9.0 billion, down from at least $10.0 billion [2] - The company anticipates fiscal 2026 revenue of at least $400 billion, below the consensus of $409.77 billion, with adjusted operating income projected between $15.07 billion and $15.41 billion [2] Group 3 - Bank of America Securities views the reaffirmation of the 2026 guidance positively amid investor concerns regarding Medicare Advantage headwinds in 2027 and regulatory scrutiny in the pharmacy benefit manager sector [3] - In Health Care Benefits, group Medicare Advantage rate renewals are seen as opportunities to improve margins, supported by progress in Individual Medicare Advantage [4] - Analyst Allen Lutz noted that CVS has several strategies to counteract headwinds from the 2027 preliminary rate notice, including share repurchases and repricing of Group Medicare Advantage [4] Group 4 - In Health Services, Bank of America expects continued margin improvement in Oak Street due to clinic closures, fewer new openings, and growing patient panels, which support a path toward break-even [5] - Overall, Bank of America sees multiple levers in place to drive CVS's enterprise growth and maintains a positive outlook on the long-term strategy, reiterating a Buy rating with a price forecast of $95 [5] - CVS Health shares were up 0.87% at $76.36 at the time of publication [5]

The countdown is on. Everything you need to get the edge at the end of the market day. Live from Studio two at Bloomberg headquarters in New York, I'm Katie Greenfield and standing next to me.Hello, Scarlet Fu. Hello. It's an it it's not even an ETF like you did, not even a monday.All right. We're kicking you off to the closing bell here in the US on this Tuesday with stocks mixed Right now, you do have the S&P 500 lower by a 10th of 1%, but we're still pretty much near record highs in terms of the gainers ...

Financial Data and Key Metrics Changes - In Q4 2025, CVS Health reported adjusted operating income of $2.6 billion and adjusted earnings per share (EPS) of $1.09, with full-year adjusted EPS of $6.75 and operating cash flow of $10.6 billion, exceeding initial expectations by approximately 15% [5][6][24]. - Full-year revenue for 2025 was over $400 billion, with Q4 revenue exceeding $105 billion, an increase of over 8% year-over-year [23][24]. Business Line Data and Key Metrics Changes - The healthcare benefits segment generated over $36 billion in revenue for Q4, a 10% increase year-over-year, but reported an adjusted operating loss of $676 million due to changes in the Medicare Part D program [25][26]. - The health services segment saw revenues of over $51 billion, a 9% increase year-over-year, with adjusted operating income of approximately $1.9 billion [28]. - The pharmacy and consumer wellness segment generated nearly $38 billion in revenue, a 12% increase year-over-year, with same-store pharmacy sales growing over 19% [29][30]. Market Data and Key Metrics Changes - The company ended 2025 with approximately 26.6 million medical members, a slight decline from the previous year, primarily due to losses in individual exchange and government businesses [25][26]. - Aetna received the inaugural Press Ganey Health Plan of the Year award, recognizing its high-quality offerings and technological innovation [7]. Company Strategy and Development Direction - CVS Health aims to simplify the healthcare experience and make it more affordable, with a commitment to becoming America's most trusted healthcare company [5]. - The company is focused on improving margins in its Medicare business while advocating for better funding to ensure adequate access for seniors [8][40]. - CVS Health is committed to leveraging its diversified business model to unlock earnings power and drive shareholder value [6][21]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's momentum entering 2026, expecting another strong year of progress despite elevated medical cost trends [33][34]. - The company remains focused on addressing the challenges of cost, complexity, and fragmentation in the U.S. healthcare system [15][21]. Other Important Information - CVS Health's pharmacy businesses are adapting to regulatory changes while maintaining durable margins, emphasizing the importance of transparency and competition in the pharmaceutical supply chain [12][19]. - The company has successfully transitioned to a cost-based reimbursement model, enhancing transparency and stability in the pharmacy market [14][31]. Q&A Session Questions and Answers Question: Impact of Medicare Advantage rates on margins - Management acknowledged the Advanced Rate Notice's impact on Aetna but remains committed to improving Medicare Advantage margins and believes the business is well-positioned despite the preliminary rates [37][39][45]. Question: Regulatory impact on PBM negotiations - Management indicated that while they cannot discuss specifics regarding the FTC, they believe the PBM value remains intact and that they are prepared for upcoming regulatory changes [51][53]. Question: Medicaid rates and expectations for 2026 - Management reported that the Medicaid business is performing in line with expectations and emphasized ongoing advocacy for adequate rates while maintaining operational excellence [72][74].

Core Insights - SelectQuote reported a strong quarter driven by effective execution during the Medicare Advantage season, achieving near-record senior EBITDA margins of 39% despite modest year-over-year growth [4][10][24] - The company has made significant advancements in its health care services segment, with revenue increasing by 26% year over year, highlighting the impact of SelectRx on the health and quality of life for seniors [4][25] - Recent changes by a national carrier partner necessitated a reduction in fiscal 2026 guidance, with an expected $20 million impact from both the carrier's marketing budget cuts and PBM reimbursement changes, totaling a $40 million aggregate impact [6][7][30] Financial Performance - SelectQuote's revenue grew by 12% year over year, totaling $537 million, driven by both senior and health care services businesses [22][24] - Senior revenue reached $262 million, growing 2% due to increased approved policy volumes, while adjusted EBITDA for the senior segment was $102 million, consistent with last year's performance [24][31] - The company expects operating cash flow for fiscal 2026 to be between $25 million and $35 million, representing a significant increase compared to the previous year [8][32] Strategic Developments - A multiyear agreement with a key pharmacy benefit manager (PBM) enhances visibility into drug reimbursement pricing, which is crucial for expanding profitability [5][37] - The new $415 million credit facility improves capital flexibility, extending debt maturities to 2031 and allowing the company to pursue growth opportunities strategically [5][29] - SelectQuote's operational model focuses on profitability and cash flow over growth, with a commitment to optimizing customer targeting and capital deployment [21][55] Market Dynamics - The Medicare Advantage market is experiencing disruptions, with a significant number of plans being terminated and changes in policy features, leading to increased consumer engagement [13][17] - SelectQuote's strategy during the AEP focused on retaining tenured agents and proactively connecting with policyholders, resulting in a policy volume growth of 4% [9][10] - The company achieved a recapture rate of 33%, indicating strong customer retention and the effectiveness of its service model in a dynamic market [15][17] Future Outlook - Despite the recent guidance reduction, SelectQuote maintains confidence in its long-term growth, profitability, and cash flow potential, with targets of over 20% EBITDA margins for the senior division and an annualized adjusted EBITDA exit rate of $40 million to $50 million for health care services [31][32] - The company is positioned to capitalize on market opportunities, leveraging its diversified model and operational efficiencies to drive shareholder value [65]

Core Viewpoint - UnitedHealth Group Incorporated (NYSE:UNH) is experiencing notable stock volatility due to Medicare Advantage advance rate announcements, with Bernstein SocGen Group maintaining an Outperform rating and a price target of $405 [1]. Group 1: Market Analysis - Analyst Lance Wilkes highlighted five key market questions regarding the surprise advance rate, its potential impact on Medicare Advantage margins, and various projections for UnitedHealth's earnings per share [3]. - TD Cowen has reduced its price target for UnitedHealth Group to $311 from $338 while retaining a Hold rating, but has upgraded its earnings per share projections for 2026 to $17.53 and for 2027 to $19.44, compared to previous estimates of $17.27 and $19.95 [4]. Group 2: Company Overview - UnitedHealth Group is a prominent US multinational corporation that provides managed healthcare and insurance services, operating through four main segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx [5].

It's been a nightmare week for health insurance stocks and it has something to do with this thing called Medicare Advantage rate. Medicare Advantage is a very important program for this country. About half of all seniors are enrolled in Medicare Advantage, which is basically where the government pays insurers to manage the care of seniors.Shares of America's largest health insurance companies. Think United Health Group and CVS cratered this week after the Trump administration announced a Medicare Advantage ...